Japan Generics Market Analysis
Japan is the world’s second largest pharmaceutical markets in the world, but due to public perception, the share of generic drugs has remained low in it. However, worried over rising healthcare expenses and high mortality rates, the government has now been playing a vital role in promoting generics. The patent expiry of branded drugs and active ingredients will also act as a strong growth driver for the market in future. According to the findings of our latest report, the generics market in Japan stood at around US$ 9 Billion in 2010. It estimates that the growth in generic drugs will outshine the expansion in overall pharmaceutical market.
According to “Japan Generics Market Analysis”, Japan is expected to be the next generic hub, and cancer related generics exhibit vast potential. The report finds out how vital is the role of National Health Insurance (NHI) pharmacies and Diagnosis Procedure Combination (DPC) hospitals in the industry development. It was observed that the DPC hospitals, in particular, have been growing at a robust rate, promoting generics penetration. We also found that ethical generics hold the majority share in the generic drugs market.
A detailed demographic analysis was carried out in the research that revealed that the population aged 65 years and above accounts for maximum healthcare-related expenditures in Japan, and hence becomes the target population for generics promotion. Further, a meticulous disease and age-wise segmentation has provided the holistic understanding of the healthcare-related demand parameters prevailing in the country.
The government in Japan has taken several initiatives to ensure growth and promotion of generics industry in the country. Recently, special premium-based incentives have been given to pharmacists on generic promotion. In near future, the government plans to bring in more reforms in medical care system. Our research talks about such revisions and reforms briefly to present a balanced outlook of the industry to clients. Analysis of current trends, profiles of key players in the Japanese generic market, and recent developments in the industry have also been included in the comprehensive study.
According to “Japan Generics Market Analysis”, Japan is expected to be the next generic hub, and cancer related generics exhibit vast potential. The report finds out how vital is the role of National Health Insurance (NHI) pharmacies and Diagnosis Procedure Combination (DPC) hospitals in the industry development. It was observed that the DPC hospitals, in particular, have been growing at a robust rate, promoting generics penetration. We also found that ethical generics hold the majority share in the generic drugs market.
A detailed demographic analysis was carried out in the research that revealed that the population aged 65 years and above accounts for maximum healthcare-related expenditures in Japan, and hence becomes the target population for generics promotion. Further, a meticulous disease and age-wise segmentation has provided the holistic understanding of the healthcare-related demand parameters prevailing in the country.
The government in Japan has taken several initiatives to ensure growth and promotion of generics industry in the country. Recently, special premium-based incentives have been given to pharmacists on generic promotion. In near future, the government plans to bring in more reforms in medical care system. Our research talks about such revisions and reforms briefly to present a balanced outlook of the industry to clients. Analysis of current trends, profiles of key players in the Japanese generic market, and recent developments in the industry have also been included in the comprehensive study.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. RECENT MARKET TRENDS
3.1 NHI Pharmacies and DPC Hospitals to Contribute Majorly in Generics
3.2 Japan: Next Generic Hub for Pharma Majors
3.3 Cancer Generics Projected for Exorbitant Growth
4. DEMOGRAPHICS PROFILE
5. THE JAPANESE PHARMACEUTICAL MARKET OUTLOOK TO 2014
6. THE JAPANESE GENERIC DRUGS MARKET OVERVIEW
6.1 Healthcare Expenditure
6.1.1 Expenditure by Disease and Age Group
6.2 Generics Penetration
6.3 Generics Market Outlook to 2014
6.4 Ethical vs OTC Generics
6.5 Distribution System
6.5.1 By Medical Institution
6.5.2 By Distribution Channel
6.6 Recent Generic Launches
7. CONSUMER BEHAVIOR ANALYSIS
7.1 Patients View
7.2 Physicians and Pharmacist View
8. REGULATORY ENVIRONMENT
8.1 Role of MHLW
8.2 Key Requirements for Generics Approval and Marketing Authorization
8.3 Patent System
9. KEY GOVERNMENT INITIATIVES
10. OPPORTUNITY ASSESSMENT
10.1 By Patent Expiration
10.2 By Therapeutic Treatment
11. KEY PLAYERS
11.1 Nichi-Iko
11.2 Sawai Pharmaceuticals
11.3 Taiyo Pharmaceutical
11.4 Towa
11.5 Meiji Seika
11.6 Nippon Chemipher
2. RESEARCH METHODOLOGY
3. RECENT MARKET TRENDS
3.1 NHI Pharmacies and DPC Hospitals to Contribute Majorly in Generics
3.2 Japan: Next Generic Hub for Pharma Majors
3.3 Cancer Generics Projected for Exorbitant Growth
4. DEMOGRAPHICS PROFILE
5. THE JAPANESE PHARMACEUTICAL MARKET OUTLOOK TO 2014
6. THE JAPANESE GENERIC DRUGS MARKET OVERVIEW
6.1 Healthcare Expenditure
6.1.1 Expenditure by Disease and Age Group
6.2 Generics Penetration
6.3 Generics Market Outlook to 2014
6.4 Ethical vs OTC Generics
6.5 Distribution System
6.5.1 By Medical Institution
6.5.2 By Distribution Channel
6.6 Recent Generic Launches
7. CONSUMER BEHAVIOR ANALYSIS
7.1 Patients View
7.2 Physicians and Pharmacist View
8. REGULATORY ENVIRONMENT
8.1 Role of MHLW
8.2 Key Requirements for Generics Approval and Marketing Authorization
8.3 Patent System
9. KEY GOVERNMENT INITIATIVES
10. OPPORTUNITY ASSESSMENT
10.1 By Patent Expiration
10.2 By Therapeutic Treatment
11. KEY PLAYERS
11.1 Nichi-Iko
11.2 Sawai Pharmaceuticals
11.3 Taiyo Pharmaceutical
11.4 Towa
11.5 Meiji Seika
11.6 Nippon Chemipher
LIST OF FIGURES
Figure 3-1: Cancer Mortality Rate (per 100,000 Population), 2000 & 2010
Figure 5-1: Pharmaceutical Market (Billion US$), 2010-2014
Figure 5-2: Share of Generics in Pharmaceutical Market (2011)
Figure 5-3: Pharmaceutical Sales by Facility (%), 2009
Figure 6-1: Healthcare Expenditure (Billion US$), 2010 & 2015
Figure 6-2: Percentage Distribution of Healthcare Expenditure by Diseases for Population Aged below 65 (2008)
Figure 6-3: Percentage Distribution of Healthcare Expenditure by Diseases for Population Aged 65 and Above (2008)
Figure 6-4: Share of Generic Drugs in Pharmaceuticals Market w.r.t Developed Countries (2009)
Figure 6-5: Generic Drugs Market (Billion US$), 2010-2014
Figure 6-6: Market Share of Generic Drugs Manufacturers (2010)
Figure 6-7: Generic Drugs Market by Segment (%), 2009
Figure 6-8: Generic Drugs Market by Medical Institution (%), 2008 & 2009
Figure 6-9: Number of DPC Hospitals (FY 2007 to FY 2010)
Figure 6-10: Generic Drugs Market by Distribution Channel (%), 2008 & 2009
Figure 11-1: Sawai Pharmaceutical - Sales by Therapeutic Category (%), FY 2010
Figure 11-2: Towa Pharmaceutical - Sales by Therapeutic Category (%), Mar 2011
Figure 3-1: Cancer Mortality Rate (per 100,000 Population), 2000 & 2010
Figure 5-1: Pharmaceutical Market (Billion US$), 2010-2014
Figure 5-2: Share of Generics in Pharmaceutical Market (2011)
Figure 5-3: Pharmaceutical Sales by Facility (%), 2009
Figure 6-1: Healthcare Expenditure (Billion US$), 2010 & 2015
Figure 6-2: Percentage Distribution of Healthcare Expenditure by Diseases for Population Aged below 65 (2008)
Figure 6-3: Percentage Distribution of Healthcare Expenditure by Diseases for Population Aged 65 and Above (2008)
Figure 6-4: Share of Generic Drugs in Pharmaceuticals Market w.r.t Developed Countries (2009)
Figure 6-5: Generic Drugs Market (Billion US$), 2010-2014
Figure 6-6: Market Share of Generic Drugs Manufacturers (2010)
Figure 6-7: Generic Drugs Market by Segment (%), 2009
Figure 6-8: Generic Drugs Market by Medical Institution (%), 2008 & 2009
Figure 6-9: Number of DPC Hospitals (FY 2007 to FY 2010)
Figure 6-10: Generic Drugs Market by Distribution Channel (%), 2008 & 2009
Figure 11-1: Sawai Pharmaceutical - Sales by Therapeutic Category (%), FY 2010
Figure 11-2: Towa Pharmaceutical - Sales by Therapeutic Category (%), Mar 2011
LIST OF TABLES
Table 3-1: Recent Industry Activities in Cancer Generics
Table 4-1: Demographic Characteristics (2010 & 2015)
Table 6-1: Recent Generic Drugs Launch of Key Players (2011)
Table 8-1: Application Fee for Manufacturing and Marketing of Generics (JPY)
Table 9-1: Key Measures for Generic Drugs Promotion
Table 10-1: Patent Expiry of Key Drugs in Japan (2012-2015)
Table 3-1: Recent Industry Activities in Cancer Generics
Table 4-1: Demographic Characteristics (2010 & 2015)
Table 6-1: Recent Generic Drugs Launch of Key Players (2011)
Table 8-1: Application Fee for Manufacturing and Marketing of Generics (JPY)
Table 9-1: Key Measures for Generic Drugs Promotion
Table 10-1: Patent Expiry of Key Drugs in Japan (2012-2015)
